Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-23
2005-08-23
Nguyen, Dave Trong (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S723000, C514S772300, C568S624000
Reexamination Certificate
active
06933286
ABSTRACT:
The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods using biologically active nononic reverse block copolymers are described. The reverse copolymers have an inner core of polyoxyethylene (POE) that is flanked on either end by polyoxpropylene (POP). The reverse block copolymers have the following formula:wherein “b” represents a number such that the molecular weight of the hydrophobe (C3H6O)bis between approximately 750 and 20,000 Daltons and “a” represents a number such that the percentage of hydrophile (C2H4O)ais between approximately 1% and 90% of the weight of the block copolymer.
REFERENCES:
patent: 2674619 (1954-04-01), Lundsted
patent: 2854378 (1958-09-01), Buckwalter
patent: 2979528 (1961-04-01), Lundsted
patent: 3022335 (1962-02-01), Lundsted
patent: 3036118 (1962-05-01), Jackson et al.
patent: 3089818 (1963-05-01), Stone
patent: 3140232 (1964-07-01), Noseworthy
patent: 3228834 (1966-01-01), Gans et al.
patent: 3450502 (1969-06-01), Hymes
patent: 3577522 (1971-05-01), Hymes
patent: 3590125 (1971-06-01), Hymes
patent: 3641240 (1972-02-01), Hymes et al.
patent: 3740421 (1973-06-01), Schmolka
patent: 3867521 (1975-02-01), Miskel et al.
patent: 3956259 (1976-05-01), Garcia et al.
patent: 4073886 (1978-02-01), Kehm
patent: 4100271 (1978-07-01), Krezanoski
patent: RE29909 (1979-02-01), Kurtz
patent: 4323560 (1982-04-01), Baschang et al.
patent: 4395393 (1983-07-01), Schmolka
patent: 4407790 (1983-10-01), Oakes et al.
patent: 4409209 (1983-10-01), Baschang et al.
patent: 4410660 (1983-10-01), Straus
patent: 4423038 (1983-12-01), Baschang et al.
patent: 4489158 (1984-12-01), Straus
patent: 4575484 (1986-03-01), Straus
patent: 4606918 (1986-08-01), Allison et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4772466 (1988-09-01), Allison et al.
patent: 4801452 (1989-01-01), Hunter et al.
patent: 4837014 (1989-06-01), Hunter et al.
patent: 4869900 (1989-09-01), Pozzi et al.
patent: 4873083 (1989-10-01), Hunter et al.
patent: 4879109 (1989-11-01), Hunter
patent: 4897263 (1990-01-01), Hunter
patent: 4902500 (1990-02-01), Jansen et al.
patent: 4937070 (1990-06-01), Hunter
patent: 4997644 (1991-03-01), Hunter
patent: 5017370 (1991-05-01), Hunter et al.
patent: 5028599 (1991-07-01), Hunter
patent: 5030448 (1991-07-01), Hunter
patent: 5032394 (1991-07-01), Hunter
patent: 5037644 (1991-08-01), Shaked et al.
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5047236 (1991-09-01), Hunter et al.
patent: 5064643 (1991-11-01), Hunter et al.
patent: 5071649 (1991-12-01), Hunter
patent: 5078995 (1992-01-01), Hunter et al.
patent: 5080894 (1992-01-01), Hunter et al.
patent: 5089260 (1992-02-01), Hunter et al.
patent: 5221495 (1993-06-01), Cao
patent: 5234683 (1993-08-01), Hunter et al.
patent: 5262170 (1993-11-01), Anderson et al.
patent: 5656611 (1997-08-01), Kabanov et al.
patent: 5824322 (1998-10-01), Balasubramanian
patent: 6093391 (2000-07-01), Kabanov et al.
patent: 6359054 (2002-03-01), Lemieux et al.
patent: 27 08 152 (1977-09-01), None
patent: 0 000 704 (1979-02-01), None
patent: 0 003 999 (1979-09-01), None
patent: 0 011 237 (1980-05-01), None
patent: 0 049 422 (1981-09-01), None
patent: 0 103 290 (1983-09-01), None
patent: 0 121 752 (1984-10-01), None
patent: 0451880 (1991-10-01), None
patent: 2 081 436 (1971-01-01), None
patent: PCT/US86/01747 (1986-08-01), None
patent: WO 91/19794 (1991-12-01), None
patent: WO 92/16484 (1992-10-01), None
patent: WO 93/08845 (1993-05-01), None
Abe et al (Biochem. Biophys. Res. Comm. 198(1): 16-24, Jan. 1994).
Verma et al (Nature 389: 239-242, 1997).
Anderson (Nature 392:25-30, 1998).
Romano et al (Stem Cells 18: 19-39, 2000).
Branch (Trends in Biochem Sci 23: 45-50, 1998).
Somia and Verma (Nature Reviews Genetics 1: 91-99, 2000).
McCluskie et al (Molecular Medicine 5(5): 287-300, 1999).
Crook (In Basic Principles of Antisense Therapeutics, Springer-Verlag, Eds, New York, pp. 1 and 4).
Muller et al (J. Amer. Coll. Cardiol. 19(2):418-432, 1992).
Reilly et al (Drug Dev. Res. 29(2): 137-147, 1993).
Lafont et al (Card. Res. 39(1): 50-59, Jul. 1998).
Lafont et al (Ann. Card. Ang. 44(7): 349-353, Sep. 1995).
Johnson et al (Thromb. Haemost 81:835-843, 1999).
Pahlson et al., “Curved Rods Related to Mobiluncus: Phenotypes as Defined by Monoclonal Antibodies; Hybridoma Generation and Monoclonal Antibody Production”, abstract, Database Medline on STN, No. 1986-10657, 1986, Columbus, OH, USA.
Atkinson, et al., “Ion Transport Mediated by Copolymers Composed of Polyoxyethylene and Polyoxypropylene,”The American Physiological Society,0363-6143/88, pp. C20-C26 (1988).
Benner, et al., “Uber die Wirkung von Pluronic® F-68, einem Polyoxypropylen-Polyoxyyyathylen-Kondensa auf die ADP-induzierte Thromobocytenaggregation in Vitro (The Effect of Pluronic® F-68, a Polyoxypropylene/Polyoxyethylene Condensate, on ADP-Induced Platelet Aggregation in Vitro)”,Pflugers Arch.,vol. 2, pp. 331-342 (1973).
Benner, et al., “Cold-Induced Platelet Aggregation in Vivo and Its Inhibition by a Nonionic Surface Active Substance”,Thrombosis Research,vol. 2, pp. 331-342 (1973).
Block, et al., “Acutely Traumatized Canine Ureter Effects of Low Molecular Weight Dextran and Surfactant Pluronic® F-68”,Urology,vol. 3, No. 2, pp. 190-194 (1974).
Block and Graft Copolymerization,vol. 2, ed. By R. J. Ceresa, John Wiley & Sons (1976).
Byars, et al., Adjuvant formulation for us in Vaccines to Elicit both Cell-Mediated and Humoral Immunology,Vaccine,vol. 5, pp. 223-228 (1987).
Confroth, et al., “Antituberculous Effect of Certain Surface-Active Ethylene Ethers in Mice”,Chemical Abstracts,vol. 46, No. 2696 (1952).
Gaehtgens, et al., “Disaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis,”Act. Heamat.,vol. 53, pp. 82-89 (1975).
Grover, et al., “A Non-Ionic Surfactant and Blood Viscosity”,Arch. Surg.,vol. 106, pp. 307-310 (1973).
Grover, et al., “The Effect of Pluronic® F-68 on Circulatory Dynamics and Renal and Carotid Artery Flow During Hemorrhagic Shock”,Journal of Surgical Research,vol. 17, pp. 30-35 (1974).
Hoie, et al., “Effects of Pluronic® F-68, Poloralkol, on Vascular Resistance in Vivo”,Journal of Surgical Research,vol. 11, pp. 515-517 (1971).
Hunter, et al., “Adjuvant Activity of Non-Ionic Block Copolymers.IV. Effect of Molecular Weight and Formulation on Titre and Isotype of Antibody”,Vaccine,vol. 9, pp. 250-256 (1991).
Hunter, et al., “Increased Whole Blood Viscosity During Coronary Bypass Surgery”,Thromb. Haemost.,vol. 63, No. 1, pp. 6-12 (1990).
Hunter, et al., “Nonionic Block Copolymers Surfactants as Immunological Adjuvants: Mechanisms of Action and Novel Formulations”,Immunological Adjuvants and Vaccines,pp. 133-144 (1989).
Hunter, et al., “The Adjuvant Activity of Nonionic Block Polymer Surfactants. I. The Role of Hydrophile-Lipophile Balance”,J. Immun.,vol. 27, No. 3, pp. 1244-1250 (1981).
Hunter, et al., “The Adjuvant Activity of Nonionic Block Polymer Surfactants. III. Characterization of Select Biologically Active Surfaces”,Scand. J. Immunol.,vol. 23, pp. 287-300 (1986).
Hymes, et al., “The Influence of an Industrial Surfactant Pluronic® F-68, In the Treatment of Hemorrhagic Shock”,Journal of Surgical Research,vol. 11, pp. 191-197 (1971).
Ketchum, et al., “Experimental Use of Pluronic® F-68 in Microvascular Surgery”,Plastic and Reconstructive Surgery,Vo.. 53, pp. 288-292 (1974).
Ketchum, L.D., “Pharmacological Alterations in the Clotting Mechanism: Use In Microvascular Surgery”,Journal of Hand Surgery,vol. 3, pp. 407-415 (1978).
Knize, et al., “Use of Anti
Allaudeen Hameedsulthan S.
Emanuele R. Martin
Kousoulas Konstantin G.
Newman Mark
Kilpatrick & Stockton LLP
Nguyen Dave Trong
Schnizer Richard
LandOfFree
Therapeutic delivery compositions and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic delivery compositions and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic delivery compositions and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3508048